EU MDR Glossary: 61 Terms You Should Know

AUTHOR
Dragan | Co-Founder & CTO
The EU Medical Device Regulation has its own vocabulary. This glossary explains 61 key terms. Where the MDR or IVDR defines a term, the entry follows that definition and names the article. Terms the regulation does not define are marked as such.
It complements our guides on whether a product is a medical device and how to classify it.
| Term | Meaning | Source |
|---|---|---|
| Active implantable medical device directive (AIMDD) | Directive 90/385/EEC, the former EU directive on active implantable medical devices. It was repealed with effect from 26 May 2021, with the exceptions listed in Article 122 MDR. | Art. 122 MDR |
| Annex XVI products | Groups of products without an intended medical purpose to which the MDR also applies, as from the date of application of the common specifications. | Art. 1(2), Annex XVI MDR |
| Authorised representative (AR) | A person established in the EU who has received and accepted a written mandate from a manufacturer located outside the EU to act on its behalf. Only manufacturers established outside the EU and the EEA need one. | Art. 2(32), Art. 11 MDR |
| Basic UDI-DI | The primary identifier of a device model, assigned at the level of the device unit of use. | Annex VI Part C MDR |
| CAPA (corrective and preventive action) | The quality management system must cover the management of corrective and preventive actions. The MDR defines corrective action as action to eliminate the cause of a potential or actual non-conformity or other undesirable situation. | Art. 2(67), Art. 10(9)(l) MDR |
| CE marking | A marking by which a manufacturer indicates that a device is in conformity with the applicable requirements of the MDR and other applicable EU harmonisation legislation providing for its affixing. | Art. 2(43), Art. 20 MDR |
| Clinical data | Information concerning safety or performance that is generated from the use of a device and comes from the sources listed in the MDR, such as clinical investigations of the device, published scientific literature on an equivalent device, and post-market surveillance. | Art. 2(48) MDR |
| Clinical development strategy | Manufacturers of class III devices and of the class IIb devices named in Article 54(1)(b) may consult an expert panel on their intended clinical development strategy and proposals for clinical investigation. | Art. 61(2) MDR |
| Clinical evaluation | A systematic and planned process to continuously generate, collect, analyse and assess the clinical data pertaining to a device. | Art. 2(44), Art. 61 MDR |
| Clinical evaluation plan (CEP) | The plan manufacturers must establish and update for the clinical evaluation, with the minimum content set out in the MDR. | Annex XIV Part A MDR |
| Clinical evaluation report (CER) | The report documenting the clinical evaluation, its results and the clinical evidence derived from it. It is part of the technical documentation, except for custom-made devices. | Art. 61(12), Annex XIV MDR |
| Clinical evidence | Clinical data and clinical evaluation results pertaining to a device of a sufficient amount and quality to allow a qualified assessment of whether the device is safe and achieves the intended clinical benefits. | Art. 2(51) MDR |
| Clinical investigation | Any systematic investigation involving one or more human subjects, undertaken to assess the safety or performance of a device. | Art. 2(45) MDR |
| Companion diagnostic | A device essential for the safe and effective use of a corresponding medicinal product, as specified in the IVDR. | Art. 2(7) IVDR |
| Competent authority | The authority or authorities each Member State designates as responsible for implementing the MDR. | Art. 101 MDR |
| Conformity assessment | The process demonstrating whether the requirements of the MDR relating to a device have been fulfilled. The risk class determines the procedure. | Art. 2(40), Art. 52 MDR |
| Declaration of conformity (DoC) | The EU declaration in which the manufacturer states that the requirements of the MDR have been fulfilled for the device covered. Its content is set out in Annex IV and includes the Basic UDI-DI and the risk class. | Art. 19, Annex IV MDR |
| Device risk class | Medical devices are divided into classes I, IIa, IIb and III, taking into account their intended purpose and inherent risks, under the rules in Annex VIII. | Art. 51, Annex VIII MDR |
| Distributor | Any person in the supply chain, other than the manufacturer or the importer, that makes a device available on the market, up until the point of putting into service. | Art. 2(34) MDR |
| Economic operator | A manufacturer, an authorised representative, an importer, a distributor or the person referred to in Article 22(1) and (3). | Art. 2(35) MDR |
| EDC (electronic data capture) | Software for collecting clinical data electronically. This is an industry term. | Not defined in the MDR |
| EMDN (European Medical Device Nomenclature) | The nomenclature used under the MDR to register devices. Article 26 requires the Commission to ensure that an internationally recognised medical devices nomenclature is available. | Art. 26 MDR; MDCG 2021-12 rev.2 |
| EUDAMED | The European database on medical devices. Four modules have been mandatory since 28 May 2026: actors, UDI and device registration, notified bodies and certificates, and market surveillance (for competent authorities and the Commission). | Art. 33 MDR; European Commission |
| Field safety corrective action (FSCA) | Corrective action taken by a manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident in relation to a device made available on the market. | Art. 2(68), Art. 87 MDR |
| Field safety notice (FSN) | A communication sent by a manufacturer to users or customers in relation to a field safety corrective action. | Art. 2(69), Art. 89(8) MDR |
| Implant card | The card delivered with an implantable device, carrying the identification information set out in Article 18. Some implants are exempted. | Art. 18 MDR |
| Importer | Any person established in the EU that places a device from a third country on the EU market. | Art. 2(33) MDR |
| In vitro diagnostic medical device (IVD) | Any medical device that is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, piece of equipment, software or system intended for the in vitro examination of specimens, as set out in the IVDR. | Art. 2(2) IVDR |
| In Vitro Diagnostic Regulation (IVDR) | Regulation (EU) 2017/746. It has applied since 26 May 2022 and repealed Directive 98/79/EC from that date, with exceptions. | Art. 112, Art. 113 IVDR |
| Intended purpose | The use for which a device is intended according to the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified in the clinical evaluation. | Art. 2(12) MDR |
| ISO 13485:2016 | The MDR does not name this standard; the requirement for a quality management system is in Article 10(9). | Not defined in the MDR |
| Legacy device | A device that may continue to be placed on the market after the MDR's date of application under Article 120. This is a guidance term. | Art. 120 MDR; MDCG 2021-25 rev.1 |
| Manufacturer | A person who manufactures or fully refurbishes a device or has a device designed, manufactured or fully refurbished, and markets that device under its name or trade mark. | Art. 2(30) MDR |
| Medical device | See the definition in Article 2(1): an article intended by the manufacturer to be used for human beings for one or more specific medical purposes, not achieving its principal action by pharmacological, immunological or metabolic means. | Art. 2(1) MDR |
| Medical Device Coordination Group (MDCG) | Group established by the MDR. Its tasks include contributing to the development of guidance. MDCG documents are not legally binding. | Art. 103, Art. 105 MDR |
| Medical Device Directive (MDD) | Directive 93/42/EEC, the former EU medical device directive. It was repealed with effect from 26 May 2021, with exceptions, when the MDR began to apply. | Art. 122, Art. 123(2) MDR |
| NANDO | The database of notified bodies developed and managed by the European Commission. It is part of the Single Market Compliance Space. | Art. 42 MDR |
| Notified body (NB) | A conformity assessment body designated in accordance with the MDR. See our list of notified bodies. | Art. 2(42) MDR |
| Performance evaluation | Under the IVDR, an assessment and analysis of data to establish or verify the scientific validity, the analytical and, where applicable, the clinical performance of a device. | Art. 2(44) IVDR |
| Performance study | Under the IVDR, a study undertaken to establish or confirm the analytical or clinical performance of a device. | Art. 2(42) IVDR |
| Periodic safety update report (PSUR) | Report by manufacturers of class IIa, IIb and III devices. Class IIb and III: updated at least annually. Class IIa: updated when necessary and at least every two years. | Art. 86 MDR |
| Person responsible for regulatory compliance (PRRC) | Manufacturers must have at least one person responsible for regulatory compliance with the requisite expertise. Micro and small enterprises need only have such a person permanently and continuously at their disposal. | Art. 15 MDR |
| PMCF (post-market clinical follow-up) | A continuous process that updates the clinical evaluation. It applies to manufacturers of all device classes; if it is not applicable, a justification is required in the post-market surveillance plan. | Art. 10(3), Annex XIV Part B, Annex III MDR |
| PMCF investigation | A clinical investigation undertaken to further assess, within the scope of its intended purpose, a device already bearing the CE marking. Studies under the PMCF plan are named as an example method. | Art. 74, Annex XIV Part B MDR |
| PMCF plan | The plan that specifies the methods and procedures for proactively collecting and evaluating clinical data. Its content is set out in Annex XIV. | Annex XIV Section 6 MDR |
| Post-market surveillance (PMS) | All activities carried out by manufacturers in cooperation with other economic operators to institute and keep up to date a systematic procedure to proactively collect and review experience gained from devices placed on the market. | Art. 2(60), Art. 83 MDR |
| Post-market surveillance plan | The plan on which the post-market surveillance system is based. Its requirements are set out in Annex III, Section 1. | Art. 84, Annex III MDR |
| Post-market surveillance report (PMSR) | Report that manufacturers of class I devices must prepare. Classes IIa, IIb and III prepare a PSUR instead. | Art. 85 MDR |
| Quality management system (QMS) | The system manufacturers of devices other than investigational devices must establish, document, implement, maintain, keep up to date and continually improve. Article 10(9) lists the aspects it must cover. | Art. 10(9) MDR |
| Reprocessing | A process carried out on a used device in order to allow its safe reuse, including cleaning, disinfection, sterilisation and related procedures, as well as testing and restoring its technical and functional safety. | Art. 2(39), Art. 17 MDR |
| Risk management system | The system manufacturers must establish, implement, document and maintain as a continuous iterative process throughout the entire lifecycle of a device. | Art. 10(2), Annex I Section 3 MDR |
| Serious adverse event (SAE) | In a clinical investigation, an adverse event that led to death or to serious deterioration in the health of the subject, among the other outcomes the MDR lists. Do not confuse it with a serious incident on the market. | Art. 2(58) MDR |
| Serious incident | Any incident that directly or indirectly led, might have led or might lead to the outcomes listed in the MDR, such as the death of a patient, user or other person, or a serious deterioration of their state of health. | Art. 2(65) MDR |
| Significant change | Legacy devices keep their transition period only if there are no significant changes in the design and intended purpose. The MDR does not define the term; MDCG 2020-3 rev.1 gives guidance. | Art. 120(3c)(b) MDR; MDCG 2020-3 rev.1 |
| Single-use device | A device that is intended to be used on one individual during a single procedure. | Art. 2(8), Art. 17 MDR |
| State of the art | Used throughout the MDR, for example in Annex I, Section 1 ("generally acknowledged state of the art"), but not defined. | Not defined in the MDR |
| Summary of safety and clinical performance (SSCP) | Summary that manufacturers of implantable and class III devices, other than custom-made or investigational devices, must draw up. | Art. 32 MDR |
| Technical documentation | Documentation that manufacturers of devices other than custom-made devices must draw up and keep up to date, with the elements set out in Annexes II and III. How far a notified body reviews it depends on the class. | Art. 10(4), Annexes II and III, Art. 52 MDR |
| Traceability | The UDI system shall allow the identification and facilitate the traceability of devices, other than custom-made and investigational devices. | Art. 27, Annex VI MDR |
| Transition period | The MDR has applied since 26 May 2021. Legacy devices may be placed on the market until 31 December 2027 or 31 December 2028, depending on the class and under the conditions of Article 120. | Art. 120, Art. 123 MDR |
| UDI (unique device identifier) | A series of numeric or alphanumeric characters created through internationally accepted device identification and coding standards that allows unambiguous identification of specific devices on the market. It consists of a UDI-DI and a UDI-PI. | Art. 2(15), Art. 27 MDR |
Sources
- Regulation (EU) 2017/745 (MDR), consolidated version of 9 November 2026
- Regulation (EU) 2017/746 (IVDR), consolidated version of 10 January 2025
- MDCG endorsed documents and other guidance
- European Commission, EUDAMED
General information, not legal advice. Legal status as of 9 November 2026.



